[This corrects the article DOI: 10.1002/cdt3.13.].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10914005 | PMC |
| http://dx.doi.org/10.1002/cdt3.93 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Real-World Data Analysis of Alglucosidase Alfa in the FDA Adverse Event Reporting System (FAERS) Database.
Drugs R D
January 2025
Department of Pediatric Intensive Care Unit, Shandong, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 324 Jingwu Road, Ji'nan, Shandong, China.
Background And Objective: Alglucosidase alfa for injection is used as an enzyme replacement therapy for the treatment of Pompe disease. The safety profile of alglucosidase alfa-associated adverse events requires a comprehensive evaluation. In this study, we aimed to identify drug safety alert signals and investigate the real-world safety of alglucosidase alfa to guide clinical decision making and optimize the risk-benefit balance.
View Article and Find Full Text PDFThe rise of weekly insulins: addressing the challenges of type 2 diabetes care in Brazil.
Diabetol Metab Syndr
January 2025
Serviço de Endocrinologia (SEMPR) do Hospital das Clínicas da Universidade Federal do Paraná (UFPR), Curitiba, Brazil.
Background: Type 2 diabetes mellitus (T2D) is a global health concern with a rising prevalence, particularly in Brazil. Insulin therapy plays a crucial role in managing T2D, helping to maintain glucose and energy homeostasis. Moreover, early initiation of insulin is crucial for hyperglycemic control and prevention of chronic complications.
View Article and Find Full Text PDF[Subcutaneous Injection of Efgartigimod, a New Therapeutic Agent for Generalized Myasthenia Gravis].
Brain Nerve
January 2025
Department of Neurology, Graduate School of Medicine, Chiba University.
Article Synopsis
- Patients with generalized myasthenia gravis (gMG) face serious physical and social challenges, and while immunotherapy has been common, not all patients find relief.
- Recent advancements have led to the development of new therapies like efgartigimod alf a, which is an intravenous treatment, now combined with vorhyaluronidase alfa for easier subcutaneous administration and better absorption.
- Clinical trials, including the ADAPT-SC study, show that this new subcutaneous treatment is as effective as the intravenous form, with promising long-term safety and benefits, making it more convenient for patients and healthcare providers.
Optimal Use of Once-Weekly Basal Insulin Efsitora Alfa in Type 1 and Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Endocr Pract
December 2024
Department of Endocrinology, Indraprastha Apollo Hospitals, New Delhi, Delhi, India.
Objective: No meta-analysis has holistically analyzed and summarized the efficacy and safety of the novel once-weekly basal insulin efsitora alfa in managing type 1 diabetes (T1D) and type 2 diabetes (T2D).
Methods: Clinical trials involving subjects with T1D and T2D receiving once-weekly efsitora alfa in the intervention arm and once-daily basal insulins in the control arm were searched throughout the electronic databases. The primary outcome assessed was the change from baseline in glycated hemoglobin (HbA1c).
Long-Term Performance and Safety of a Superficial HA Filler With Tri-Hyal Technology on Different Facial Zones: Forehead, Cheeks, Crow's Feet, and Upper Lips.
J Cosmet Dermatol
January 2025
Laboratoires FILL-MED, Paris, France.
Background: The function of injectable hyaluronic acid-based fillers is to smooth dermal wrinkles formed during aging. The aim of this study is to evaluate the performance and safety of a dermal filler after its commercialization.
Methods: In this context, an 18-month prospective randomized single-blind study for the efficacy and safety of ART FILLER Fine Lines (AFFL) was performed on the forehead, the upper lip, the cheek folds, and the crow's feet.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!